blue-check Principles of selection of control drugs used for bioequivalence study

Official letter No. 2119/QLD-DK dated March 28th, 2022 of the Drug Administration of Vietnam regarding selection of control drugs used for bioequivalence study for drugs registration
Posted: 29/3/2022 9:05:29 AM | Latest updated: 11/4/2022 10:32:35 PM (GMT+7) | LuatVietnam: 5424 | Vietlaw: 558

The Drug Administration of Vietnam notes that the selection of control drugs for bioequivalence study for drugs registration must comply with Circular No. 08/2010/TT-BYTstatus1 and these principles:

1. It is prioritized to select an invention drug that is circulating in Vietnam as a control drug or it may use an invention drug that has been licensed and is being circulated in one of the member countries of international Conference on harmony (ICH).

2. In case the study used control drug being invention drug but the invention drug is not being circulated in Vietnam, the registration establishment is required to provide data demonstrating the ability to replace each other between the drug which has been used for study and the drug which is being circulated in Vietnam according to the regulations at clause 1 Article 5 of Circular No. 08/2010/TT-BYTstatus1 .

3. Shipment of the control drug used for bioequivalence study and shipment of the control drug used for study demonstrating the ability to replace each other at point 2 above is not required the same shipment.

Ms Phuong Thao (
Please tag for reposting this article

Related documents

Penalty document



Effective Date Unknown
ExpiredDate Unknown
Published Vietlaw's Newsletter No. 558

Files attachment

enflag pdficon CV2119-28032022QLD[VLO].pdf


No data

Pharmaceutical - Cosmetics

blue-check Notable regulations on putting cosmetic products on market
blue-check From May 4th, 2023: Applications for marketing authorization of drugs shall be wholly submitted online
blue-check [Merged] - Regulations on Goods Manufacturing Practices for pharmaceutical products
blue-check Amendments to regulations on bidding for supply of drugs for public health facilities
blue-check Conditions for entitlement to 5% VAT with regard to imported veterinary drugs
blue-check New procedures for inspection of GMP compliance of manufacturers
blue-check List of precious, rare and endemic medicinal plant species under control
blue-check Withdrawal of 6 companies from the List of foreign companies committing drug’s quality
blue-check Amendments to principles to apply GMP standards for manufacture of pharmaceutical products and pharmaceutical starting materials
blue-check Manufacturers of veterinary drugs may apply for the GMP Certificate online
blue-check Amendments to conditions on import of veterinary drugs containing precursors
blue-check It is expected to remove procedures for confirmation of cosmetic advertisements under the 2022 - 2025 road map
blue-check Plants imported for use as medicines have to comply with regulations provided for the pharmacy sector
blue-check Guidance on development of rare herb planting projects supported by the State in the 2021 - 2025 period
blue-check New regulations on drugs subject to bioequivalence study during application for marketing authorization
blue-check New regulations on marketing authorization of drugs
blue-check Advertisements for drugs’ incorrect utilities shall be stopped
blue-check List of foreign companies having drugs that do not conform to quality standards (phase 36)
blue-check Principles of selection of control drugs used for bioequivalence study